Sign In
Buy PDSB
$1.08
-0.0800 (-6.90%)
At Close: Jun 03, 2026
PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time
08:00am, Wednesday, 06'th Nov 2024
PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how
PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know
01:06pm, Tuesday, 22'nd Oct 2024
PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for October 15th
11:00am, Tuesday, 15'th Oct 2024
ORLA, BABA and PDSB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 15, 2024.
100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully treated with Versamune ® HPV combined with chemoradiation (N=8) 88% (15/17) of patients had a complet
PDS Biotechnology: Continuing The Holding Pattern
10:39am, Monday, 23'rd Sep 2024
PDS Biotechnology is focusing on an HPV-directed immunotherapy as its main near-term hope, with new data presented at the ESMO Congress. Strengths include promising clinical data and a focused pipelin
PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024
08:00am, Monday, 09'th Sep 2024
PRINCETON, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming ho
PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
08:00am, Tuesday, 03'rd Sep 2024
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming ho
PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024
08:00am, Wednesday, 07'th Aug 2024
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how
PDS Biotechnology Corporation (PDSB) Clinical Program Update Conference Call (Transcript)
09:12am, Friday, 02'nd Aug 2024
PDS Biotechnology Corporation (NASDAQ:PDSB ) Clinical Program Update Conference Call August 1, 2024 8:00 AM ET Company Participants Mike Moyer - LifeSci Advisors Frank Bedu-Addo - Chief Executive Offi
PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer
07:45am, Thursday, 01'st Aug 2024
Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J.
PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time
04:01pm, Wednesday, 31'st Jul 2024
PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
08:00am, Wednesday, 15'th May 2024
Provided Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
30 month median overall survival (OS); median OS independent of patient CPS score ORR 34% (CPS≥1); 48% (CPS≥20) Phase 3 registrational trial planned to initiate in 2024 PRINCETON, N.J., May 09, 20
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024
08:00am, Tuesday, 07'th May 2024
PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how
PDS Biotechnology Announces Details of Virtual KOL Event
08:00am, Friday, 03'rd May 2024
Virtual Webinar Updated VERSATILE-002 Phase 2 Trial Results, Unmet Treatment Needs in Advanced Head and Neck Cancer and Planned Triple Combination Trial to be held May 8, 2024 Virtual Webinar Updated
